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Design, synthesis and evaluation of benzofuran-acetamide 
scaffold as potential anticonvulsant agent
A series of N-(2-(benzoyl/4-chlorobenzoyl)-benzofuran-
3-yl)-2-(substituted)-acetamide derivatives (4a-l, 5a-l) 
was synthesized in good yield. All synthesized com-
pounds were in agreement with elemental and spectral 
data. The anticonvulsant activity of all synthesized com-
pounds was assessed against the maximal electroshock 
induced seizu res (MES) model in mice. Neurotoxicity 
was evaluat ed us ing the rotarod method. The majority of 
compounds exhibited anticonvulsant activity at a dose of 
30 mg kg–1 body mass during 0.5–4 h, indicating their 
ability to prevent seizure spread at low doses. Relative to 
phenytoin, [N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-
(cyclo hexyl(meth yl)amino)-acetamide] (5i) and [N-(2-(4-
chlorobenzoyl)benzofuran-3-yl)-2-(4-methylpiperidin-1-
yl)-acetamide] (5c) demonstrated comparable relative 
anticonvulsant potency of 0.74 and 0.72, respectively, 
whereas [(N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-
(furan-2-carbonyl)-piperazin-1-yl)-acetamide] (5f) exhib-
ited the lowest relative potency of 0.16. The ALD50 of 
tested compounds ranged from 1.604 to 1.675 mmol kg–1 
body mass. The ED50 of synthesized compounds ranged 
from 0.055 to 0.259 mmol kg–1 (~23.4 to 127.6 mg kg–1) body 
mass. The pharmacophore mapping of the examined 
com pounds on standard drugs (phenobarbital, phenyto-
in, ralitolin and carbamazepine) strongly suggests that 
these compounds may exert their anticonvulsant activity 
via the same established mechanism as that of known 
drugs.
Keywords: benzofuran, anticonvulsant, neurotoxicity, 
GABA-AT, pharmacophore modeling, docking, Molegro 
Virtual Docker 4.0
Epilepsy is one of the most common and serious neurological disorders characterized 
by recurrent seizures resulting from a temporary electrical disturbance of the brain. World-
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in developing countries (1). Unfortunately, 20–30 % of epileptic patients have seizures that 
are resistant to available medical therapies. In addition, all currently approved antiepileptic 
drugs have dose related toxicity and idiosyncratic side effects (2). The most commonly re-
ported side effects are drowsiness, ataxia, gastrointestinal disturbances, hepatotoxicity, gin-
gival hyperplasia, hirsutism and megaloblastic anaemia (3, 4). Phenytoin, carbamazepine, 
lamotrigine, sulfamate and topiramate are recent antiepileptic drugs clinically effective 
against different types of seizures (5). Despite rapid progress in the development of new 
antiepileptic compounds, no single treatment is satisfactory in preventing and controlling 
seizures (6–8). Therefore, developing new antiepileptic agents with improved therapeutic 
properties has been the focus of research groups and a hot target for medicinal chemists.
Amides are a class of compounds presenting a wide range of biological applications and 
anticonvulsant activity (9, 10). It has been reported earlier (11) that anticonvulsant com-
pounds require the following essential features: (i) a hydrophobic aryl ring, (ii) a hydrogen 
bonding domain, (iii) an electron donor acceptor system and (iv) another hydrophobic aryl 
ring responsible for the metabolism. These essential features are present in most popular 
anticonvulsant drugs such as phenytoin, carbamazepine, phenobarbital and ralitoline. Ben-
zofuran derivatives have diverse pharmacological activities, like anticonvulsant (12–15), 
antiinflammatory (13), analgesic (16), antioxidant and antimicrobial (17, 18), neuroprotective 
(19), anticancer, cytotoxic, inhibiting of NF-κB and protein kinase (20–22). Benzofuran, a 
versatile heterocyclic molecule possessing a preliminary anticonvulsant property, has been 
selected to explore as a hydrophobic functional group for the binding site.
Gamma-aminobutyric acid (GABA) is the main neurotransmitter in the CNS respon-
sible for the maintenance of the inhibitory tone that counterbalances neuronal excitation. 
A GABA antagonist causes seizures while a GABA agonist suppresses seizures. Most an-
ticonvulsant drugs possess activity via GABA mediation. Keeping this in mind, active 
compounds were screened for neurochemical estimation of the GABA level in brain.
In the present work, our objective was to design and synthesize new compounds hav-
ing benzofuran moiety coupled with substituted amines via acetamide linkage hoping to get 
compounds with enhanced bioactivity and to study their binding properties with 
γ-aminobutyric acid-aminotransferase (GABA-AT). All the compounds were evaluated for 
their antiepileptic and neurotoxic properties according to the protocols of the Antiepileptic 
Drug Development (ADD) program developed by the National Institute of Health (NIH). In 
order to explore the common pharmacophore of these compounds, we investigated the syn-
thesized series of compounds by means of the computer aided drug design through ligand 
based approaches. Pharmacophore modeling tool was selected for this study.
The literature reveals a large number of successful applications of the pharmacophore 
based virtual screening protocols in the modern drug discovery paradigm (23, 24). The 
Hip Hop algorithm finds the common feature pharmacophore model in the set of highly 
active ligands and is thus regarded as qualitative model without the use of activity data 
representing the 3D arrangement of the essential features important for the specific activ-
ity. The molecular docking approach is one of the most rational and authentic approaches 
in drug design and discovery for studying molecular interactions of small molecules. 
Docking involves two main components, the search algorithm and scoring functions. The 
search algorithm involves the positioning of molecular conformations in the active site 
while the scoring function determines energetically most favourable orientation of the 
molecule. In this study, we have used the Molegro virtual docker 4.0 program with its 
piecewise linear potential (PLP) based algorithm for docking of all synthesized com-
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pounds in the GABA-AT binding site, which was also previously reported by many au-
thors (25, 26). We have also calculated the binding affinities of these compounds compared 
to standard reference compounds.
EXPERIMENTAL
Chemistry
All the chemicals and solvents used in the study were purchased from Merck (Ger-
many), Sigma-Aldrich (USA/India) and Acros (Belgium) and were used without further 
purification. Melting points were determined in open glass capillaries using a melting 
point apparatus (Veego, India) and were uncorrected. The IR spectra were measured using 
a Mattson ATI Genesis FT-IR Spectrometer (Mattson Instruments, USA). 1H NMR and 
13C NMR spectra of selected compounds were recorded on a Bruker model DRX-300 NMR 
spectrometer (Bruker BioSpin Corporation, USA) in CDCl3/DMSO-d6 using tetramethylsi-
lane (TMS) as internal reference. Chemical shifts are reported in parts per million (ppm, 
δ) and signals are described as s (singlet), d (doublet), t (triplet), q (quartet) and m (multi-
plet). The electrospray mass spectra were recorded on a Micromass Quattro II triple-quad-
rupole mass spectrometer (Micromass, UK). Elemental analyses (C, H and N) were per-
formed on a Perkin-Elmer model 240 analyzer (PerkinElmer, USA) and were found within 
the range of ± 0.4 % of theoretical values. Purity of the compounds and the progress of 
reaction were checked by thin layer chromatography (TLC) on silica gel G plates (Quali-
gens, India) using cyclohexane/ethyl acetate (8:2) as a solvent system and the spots were 
located either under UV light or by exposure to iodine vapors.
Syntheses
2-(Benzoyl-methoxy)benzonitrile (1a), 2-[2-(4-chlorophenyl)-2-oxyethoxy]benzonitrile (1b), 
2-benzoyl-1-benzofuran-3-amine (2a) and 2-(4-chlorobenzoyl)-1-benzofuran-3-amine (2b) and 
N-(2-benzoyl-benzofuran-3-yl)-2-chloroacetamide (3a) were prepared following the reported 
methods (12, 16).
N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-chloroacetamide (3b). – 3-Amino-2-(4-chloro-
ben zoyl)benzofuran (2b, 20 mmol) and 4-dimethylamino-pyridine (DIMAP, 2 mmol) were 
dissolved in dioxane (20 mL). Chloroacetyl chloride (22 mmol) was added in small portions 
for 30 min. The reaction mixture was stirred at room temperature and then warmed on a 
water bath for 5 h. After cooling, reaction mixture was poured into ice water with stirring. 
The solid that separated was collected and recrystallized from benzene.
N-(2-(benzoyl/4-chlorobenzoyl)benzofuran-3-yl)-2-(substituted)-acetamides (4a-l, 5a-l). General 
procedure. – To a well stirred solution of N-(2-(4-benzoyl/4-chlorobenzoyl)benzofuran-3-yl)-
2-chloroacetamide (3a/3b, 1 mmol) in dioxane (10 mL), different amines (2 mmol) were 
added separately and the reaction mixture was refluxed for 4 h. The reaction mixture was 
cooled and poured in water. The residue which separated was collected and recrystallized 
from ethanol.
The physicochemical properties and spectral data of synthesized compounds 3b, 4a-l, 
5a-l are given in Table I.
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Animals and general procedures. – Male albino Swiss mice (20–30 g) and Wistar rats 
(125–160 g) were used as experimental animals. Animals were housed and kept in accor-
dance with the Integral University Lucknow animal care unit. Experiments were approved 
by the institutional Ethical Committee. The animals were housed in groups of 6 animals 
and acclimatized to room conditions for at least 2 days prior to the experiments. Anticon-
vulsant evaluations were undertaken using the reported procedure (27). Test compounds 
and the standard drug (in 0.5 % methylcellulose) were administered intraperitoneally. The 
rotarod test was used to evaluate neurotoxicity (28). The level of GABA in brain tissues of 
rats was estimated enzymatically as previously described (29). Approximate lethal dose 
(ALD50) of the selected compounds was determined according to the literature (30).
Anticonvulsant activity. – Animals (mice) were maintained at an adequate diet and al-
lowed free access to food and water except for a short period during which they were re-
moved from the cages for testing. The animals were screened 24 hours prior to experiment. 
A 50-mA current was given to the pinna of the animals for 0.25 s using a Medicraft® 
Electro-Convulseometer (Medicraft Electro Medicals (P) Ltd, India). Normal saline was 
used as the conducting medium between the electrode and pinna. Only those animals 
which produced tonic convulsions were selected. The maximal seizure usually consisted 
of a short period of tonic extension of the hind limbs and the final clonic episode. Next day, 
the selected animals were divided into groups and compounds were administered intra-
peritoneally (doses of 30, 100 or 300 mg kg–1 body mass). After 30 min and 4 hours of drug 
administration, electroshock was applied. Disappearance of the hind limb tonic extensor 
component of convulsion was considered positive criterion for anticonvulsant activity.
Neurotoxicity screening. – Minimal motor impairment was measured in mice by the 
rotarod test. The mice were trained to stay on an accelerating knurled rod (diameter 3.2 
cm) rotating at 6 revolutions per min. Only those animals which demonstrated their capa-
bility to remain on the revolving rod for at least 1 min were considered for the test; these 
mice were considered as trained mice. Trained mice can remain on a rod rotating at this 
speed indefinitely. These trained mice were given test compounds or phenytoin in doses 
of 30, 100 and 300 mg kg–1. Thirty minutes after administration, the mice were placed on 
the rotating rod. Neurological toxicity is defined as the failure of the animal to remain on 
the rod for at least 1 min in each of the three trials.
In order to explore the mechanism of anticonvulsant activity of these derivatives, 
most active compounds (5i and 5c) were subjected to neurochemical investigation to de-
termine the GABA level in brain tissue extracts. 
GABA level in brain. – Adult Wistar rats were divided into three groups of three ani-
mals each. After 2 h of clobazam (30 mg kg–1 body mass) or test compound (5c or 5i, 100 mg 
kg–1 body mass) administration, the animals were decapitated and the brain regions, mid 
brain, cerebellum and medulla oblongata were dropped into separate vessels containing 
4~6 mL of ice cold 80 % ethanol and processed further as per the reported procedure (29).
The effective 50 % dose values (ED50) of compounds were calculated using the XL-
STAT software version 2012.2.01 (Addinsoft, Paris, France) on the basis of maximum effect 
observed after 0.5 h.
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Lethal dose (LD50). – The animals (mice) were divided into different groups of four 
animals each. These were administered 215, 464, 1000 and 2150 mg kg–1 of drugs intra-
peritoneally and observations were made for mortality up to 24 hours. The lethal dose was 
calculated as reported earlier (30).
Computational methods
All molecular modeling works were accomplished using the Window-based Accelrys 
Discovery Studio version 2.0 (DS 2.0, Accelrys Inc., USA). All structures were generated 
using the 2D/3D editor minimized to the closest minimum using the CHARMM-like force 
field implemented in the program (31). Stochastic method coupled with poling algorithm 
was used to generate conformers for each compound by using the best conformation gen-
eration method with 20 kcal mol–1 energy cutoff. The catalyst based pharmacophore gen-
eration involved the HipHop algorithm for the generation of 3D pharmacophore align-
ment. The procedure for the generation of pharmacophore involved as per reported 
protocols generation of a conformational model for each training set of compounds fol-
lowed by examination of each conformation for the presence of important chemical fea-
tures (31). Finally, a 3D configuration of a chemical feature common to the input molecules 
was determined. Catalyst defines the important feature of compounds in the drug-en-
zyme/receptor interactions. These are hydrogen bond donors, hydrogen bond acceptors, 
hydrophobic groups, aromatic ring and positive and negative ionisable groups. For the 
pharmacophore modeling runs, common features selected for the run were ring aromatic 
(R), hydrogen bond donor (D), hydrogen bond acceptor (A), hydrophobic group (H), posi-
tive ionisable group (P).
Molecular modeling and docking studies
Moldock software version 4.1.0 (CLC bio, Aarhus, Denmark) combines the differential 
evolution algorithm with the cavity prediction algorithm. Previously, only differential 
evolution was applied to molecular docking, which, when combined with the cavity pre-
diction algorithm, results in fast and accurate binding modes. The scoring function in 
Moldock is based on the Piecewise Linear Potential (PLP), which was introduced by Gehl-
haar et al. (32) and further extended by Yang and Chen (33) in GEMDOCK. In this case, the 
hydrogen bond directionality was taken in account to improve the Moldock scoring func-
tions. The reported co-crystal structure of 4-aminobutyrate-aminotransferase (GABA-AT) 
from pig (1OHV) was obtained from Brookhaven Protein Data Bank (PDB). The PDB ID 
1OHV was prepared using the docking algorithm by assigning the bond orders, if missing, 
charges and flexible torsions. This protein was again prepared initially by considering the 
protein without ligand and water molecules. The backbone was fixed, the CharmM force 
field and minimization using the steep descent algorithm were applied for 1OHV. This 
prepared protein structure was used for docking experiments. The structures of two most 
active compounds used in this study were drawn in Chemdraw ultra 12 and imported in 
Discovery Studio 2.0 (Telesis Court, San Diego, CA, USA) for minimizing it up to a gradient 
of 0.01 kcal mol–1 Å–1 using the CharmM forces field. In the Molegro docking wizard, the 
prepared protein was imported and potential binding sites were calculated using the cav-
ity detection algorithm in the Moldock optimizer. The radius of the docking search sphere 
was set to 10 Ǻ around Lys-329 since vigabtrin, the standard drug, forms a covalent ter-
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nary adduct with the active site Lys-329. The cavity detection algorithm (guided differen-
tial evolution) was used to focus the search during docking runs. The parameters were 
fixed for docking runs as: number of runs 10, population size 50, crossover rate 0.9, scaling 
factor 0.5 and maximum iterations 2000. To retain the best scoring pose, pose clustering 
was applied and the best five top scoring poses were retained. Fitness scores calculated by 
the Moldock scoring 0.5 function were then evaluated.
RESULTS AND DISCUSSION
Chemistry
The title compounds, N-(2-(4-benzoyl/chlorobenzoyl)benzofuran-3-yl)-2-(substitut-
ed)-acetamides (4a-l, 5a-l) were synthesized (Scheme 1) by refluxing 2-chloro-N-(2-(4-ben-
zoyl/chlorobenzoyl)benzofuran-3-yl)-acetamide (3a or 3b) with various substituted 
amines. Structures of compounds were confirmed by IR, 1H NMR, mass spectrometry and 
elemental analysis. 13C NMR spectra of a few selected compounds were recorded. Spectral 
data are in agreement with the proposed structures. 1H NMR spectra of compounds 
showed signals corresponding to aromatic, aliphatic, acetamide and NH protons. The sin-
glet around δ 3.30 (COCH2) and the broad singlet around δ 10.00 ppm (NH, D2O exchange-
able) indicate the presence of NHCOCH2N linkage in all compounds. Distortionless en-
hancement by polarization transfer (DEPT) experiments were employed to differentiate 
between primary and tertiary carbons from secondary and quaternary carbons. The 13C 
NMR spectra of the compounds agree with the suggested structures. Moreover, the infra-
red spectra of the synthesized compounds show characteristic absorption bands of NH 
(amide group, ~3400 cm–1), conjugated C=O (~1700 cm–1), CONH (~1665 cm–1) in addition to 
Scheme 1
Reagents and conditions: a) DMF, K2CO3, stir, 2 h; b) MeOH, MeONa, stir, 1 h; c) dioxane, DIMAP, 
ClCH2COCl, 60 °C, 5 h; d) dioxane, sec. amine (RH), reflux, 4 h, RH: piperidine 4a, 5a; 2-methyl pi-
peridine 4b, 5b; 4-methyl piperidine 4c, 5c; 2,6-dimethyl piperidine 4d, 5d; 4-ethylpiperazine 4e, 5e; 
4-(2-furanoyl)piperazine 4f, 5f; 4-(2-flurophenyl)piperazine 4g, 5g, 4-(2-pyridyl)piperazine 4h, 5h; 
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mg kg–1 (mmol kg–1)
0.5 h 4 h
4a – 2.37 36.5 0.101 0.41 100 (0.276) –
4b – 2.69 31.6 0.084 0.49 100 (0.266) –
4c – 2.70 31.6 0.084 0.49 100 (0.266) 100 (0.266)
4d – 3.01 31.6 0.081 0.51 100 (0.256) –
4e – 1.73 51.3 0.131 0.31 30 (0.077) 100 (0.255)
4f – 1.18 97.0 0.212 0.19 30 (0.066) 100 (0.219)
4g – 3.63 31.6 0.069 0.59 100 (0.219) –
4h – 2.85 31.6 0.072 0.57 100 (0.227) –
4i – 3.18 31.6 0.081 0.51 100 (0.256) 300 (0.769)
4j – 1.24 73.1 0.201 0.21 100 (0.275) –
4k – 4.73 36.5 0.079 0.52 100 (0.218) –
4l – 3.29 31.6 0.083 0.49 100 (0.264) 100 (0.264)
5a – 2.93 31.6 0.079 0.52 100 (0.252) 300 (0.756)
5b – 3.25 31.6 0.077 0.53 100 (0.243) 300 (0.730)
5c 681 (1.657) 3.26 23.4 0.057 0.72 100 (0.243) –
5d – 3.56 31.6 0.074 0.55 100 (0.235) 300 (0.706)
5e – 2.29 36.5 0.085 0.48 30 (0.070) 100 (0.235)
5f – 1.73 127.6 0.259 0.16 30 (0.061) 100 (0.203)
5g – 4.18 31.6 0.064 0.64 100 (0.203) –
5h – 3.40 36.5 0.077 0.53 100 (0.211) 300 (0.632)
5i 681 (1.604) 3.74 23.4 0.055 0.74 100 (0.236) –
5j – 1.80 73.1 0.183 0.22 100 (0.251) 300 (0.753)
5k – 5.29 36.5 0.074 0.55 30 (0.061) 100 (0.203)
5l – 1.95 56.7 0.137 0.30 30 (0.073) 100 (0.243)
Phenytoin 150 (0.595) 2.47 10.3 (6.5)b 0.041 1.00 100 (0.396) 100 (0.396)
LD50 – median lethal dose; the amount of substance required to kill 50 % of the test population.
ED50 – median effective dose; the dose that produces a quantal effect (all or nothing) in 50 % of the population.
a log P value was calculated using ChemDraw Ultra V.11.
b Experimental ED50 value of phenytoin (9).
other absorption bands correlated to the assigned structures. Mass spectral data of the 
synthesized compounds are in agreement with the assigned structures and show the ex-
pected molecular ions [M+H]+ suggested by their molecular formulae.
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All synthesized compounds were evaluated for anticonvulsant activity along with the 
neurotoxicity effect on mice. The ALD50 (i.p.) of compounds 5c and 5i were 1.604 and 1.675 
mmol kg–1 (681 mg kg–1) body mass, respectively.
Anticonvulsant activity. – Table II indicates that the anticonvulsant activity of the exam-
ined compounds was lower than that of phenytoin. ED50 values of tested compounds ranged 
from 0.055 to 0.259 mmol kg–1, while the ED50 of phenytoin was 0.041 mmol kg–1 in mice. The 
relative potencies of tested compounds with respect to phenytoin were calculated by taking 
the ratio of the ED50 of compounds over phenytoin. Among all the compounds examined, 
[N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(cyclohexyl(methyl)amino)-acetamide] (5i) and 
[N-(2-(4-chlorobenzoyl)benzofuran-3-yl)-2-(4-methylpiperidin-1-yl)-acetamide] (5c) dem-
onstrated the highest anticonvulsant activity with anticonvulsant potency relative to phe-
nytoin of 0.74 and 0.72, respectively, whereas [(N-(2- (4- chlorobenzoyl)-benzofuran-3-yl)-2-
(4-(furan-2-carbonyl)-piperazin-1-yl)-acetamide] (5f) exhibited the lowest relative potency 
of 0.16. Relative potencies of other compounds compared to phenytoin ranged from 0.21 to 
0.64.
The results showed that all the synthesized compounds (4a-l and 5a-l) were found to 
be highly active against the MES test at a dose level of 30 mg kg–1, at a 0.5 h time interval, 
indicating their ability to prevent seizure spread at a relatively low dose. The results indi-
cate that p-chlorobenzoyl derivatives 5a-l were more active than the corresponding ben-
zoyl derivatives 4a-l, probably due to higher partition coefficient and lipid solubility (log 
P). Apart from compounds 5c and 5i, compounds 4b, 4c, 4d, 4g, 4h, 4i, 4k, 4l, 5a, 5b, 5d, 5g, 
5h, and 5k showed promising activity, with ED50 values ranging from 0.064 to 0.084 mmol 
kg–1. Interestingly, it was observed that the substituted piperazine and piperidine [viz., 
4-(2-flurophenyl)piperazinyl-(4g, 5g), 4-(pyridin-2-yl-)-piperazinyl-(4h, 5h), 4-methylpiper-
idinyl-(4c, 5c), 2,6-dimethylpiperidinyl-(4d, 5d), 2-methylpiperidinyl (4b, 5b) and piperidi-
nyl 5a] derivatives were more active than other derivatives.
Neurotoxicity. – It is noteworthy that compound 5k was more neurotoxic than the cor-
responding benzoyl derivative [N-(2-benzoylbenzofuran-3-yl)-2-(dicyclohexylamino)-acet-
amide] (4k) in spite of retaining the same effective doses. On the other hand, log P value 
Table III. GABA assay for active compounds 5i and 5c
Compound (dose)
GABA concentration (µg per 100 mg)a
Midbrain Medulla oblongata Cerebellum
Control 32.12 ± 3.85 28.24 ± 3.84 21.45 ± 2.18
5i (100 mg kg–1, 0.236 mmol kg—1)b 56.45 ± 3.14 40.21 ± 3.82 31.25 ± 2.25
5c (100 mg kg–1, 0.243 mmol kg—1)b 44.37 ± 2.45 36.07 ± 2.91 29.54 ± 2.50
Clobazam (30 mg kg–1, 0.100 mmol kg—1)b 64.14 ± 3.08 49.45 ± 2.12 38.45 ± 2.18
a Mean ± SEM, n = 3.
b Significant increase vs. control (p < 0.05).
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appears to significantly reduce potency and increase neurotoxicity of the compounds. 
Among all compounds, 4e, 4f, 5e, 5f, 5k and 5l showed neurotoxicity even at the lowest 
dose of 30 mg kg–1 (after 0.5 h) (Table II). It was observed that all the synthesized com-
pounds exerted anticonvulsant activity, which may be due to their interaction with the 
receptor site and essential pharmacophoric features present in these compounds.
GABA level in brain. – Compounds 5c, 5i and clobazam significantly increased (p < 0.05) 
the GABA level in brain compared to the control (Table III), suggesting that the observed 
anticonvulsant effect may be mediated through GABA-neurotransmission.
Pharmacophore modeling
3D pharmacophore generation. – In the pharmacophore model generation, the already 
reported protocol was used in which the highest weight was assigned to the most active 
compound 5i. The highest weight assignment was carried out by assigning the highest 
values 2 and 0 in the principal and maximum omitting features column which ensured 
mapping of all the features of this compound considering it the most active ones. All the 
remaining compounds were respectively assigned a value of 1 and 1 which ensured that 
there should be at least one mapping for each of the remaining compounds so as to develop 
a meaningful hypothesis or pharmacophore model. All other parameters were kept at de-
fault. The ten hypotheses generated had the scores ranging from 138.32 to 131.10 (Table III).
The entire ten hypotheses contain six features, two hydrogen bond acceptor (HBA) com-
mon to all hypotheses, one hydrogen bond donor (HBD), one positively ionisable (PI), one 
aromatic ring (AR) and one hydrophobic (Z). Hypo-1 was selected as it significantly maps 
all the features of most active compounds and also has maximum features. Out of the ten 
hypotheses, Hypo-1 was selected as it maps all the features of the most active compounds 
from the training set molecule. The two HBA functions map on the oxygen atom of the 
benzofuran ring and the carbonyl functionality of the methanone part of benzofuran-2-yl-
(4-chlorophenyl)-methanone of the most active compound from the training set 5i. The 
Fig. 1. Generated pharmacophore models and overlays: a) pharmacophore model for synthesized 
anticonvulsant compounds along with its inter-feature distance constraints, b) overlay of the most 
active compound 5i in the training set.
a)                                                                               b)
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hydrophobic feature maps well on the benzene ring of the benzofuran nucleus. The NH 
function of the acetamide linkage of the cyclohexyl-(methyl)-amino-acetamide part of 5i is 
mapped for the HBD function of the pharmacophore while the nitrogen atom indicates the 
PI feature of pharmacophore. Finally, the RA function of the pharmacophore is supported 
by the 4-chlorobenzoyl substitution on the benzofuran nucleus. Mapping of the most active 
compound 5i from the series 5a-l (fit value 6) on the developed pharmacophore, along with 
the pharmacophore model with inter-feature distance, is represented in Figs. 1a,b.
Ligand pharmacophore mapping. – Hypo-1 was used as a query for mapping the external 
or standard compounds used as drugs (Table IV). The drugs, viz., phenytoin, carbamaze-
pine, phenobarbital and ralitolin, were used for validation of the pharmacophore model. 
The ligand pharmacophore mapping protocol was used, allowing for the best conforma-
tion search method from the Discovery Studio 2.0 (Telesis Court, San Diego, CA, USA). The 
ligand pharmacophore mapping reveals that compounds synthesized and tested for anti-
convulsant activity have the common pharmacophore features required for the targeted 
activity. Figs. 2a-d indicate the mapping of these compounds on the developed pharmaco-
phore. The pharmacophore mapping of these compounds on standard drugs prelimina rily 
suggests that these compounds may act with the same mechanism of action as that of the 
known drugs.
Molecular modeling and docking studies. – In order to evaluate the docking results, dif-
ferent scoring functions were analyzed for the two most active compounds and the refer-
ence standard compounds. The results of the docking runs are represented in Table V. The 
most active compounds from the series were analyzed for their binding properties at the 
GABA-AT enzyme binding site at the Lys-329 residue of GABA-AT, as described (25, 26). 
Table IV. Summary of the pharmacophore models generated for the training set of compounds
Hypothesis Featuresa Rank Direct hitb Partial hitc Maximal fit
1 RPHDAA 138.973 1111111110 0000000001 6
2 RPHDA 134.672 1111111111 0000000000 5
3 RPHAA 133.891 1111111111 0000000000 5
4 RPHAA 133.891 1111111111 0000000000 5
5 RRPAA 133.89 1111111111 0000000000 5
6 RRPAA 133.89 1111111111 0000000000 5
7 RPHAA 133.887 1111111111 0000000000 5
8 RRPAA 133.702 1111111111 0000000000 5
9 PHHDAA 133.136 1111111110 0000000001 6
10 RPHAA 132.885 1111111111 0000000000 5
a  R – aromatic ring; D – hydrogen bond donor; A – hydrogen bond acceptor; H – hydrophobic group, P – positive 
ionisable group.
b  Direct hit; all features of the hypothesis are mapped. Direct hit = 1 means „yes” and direct hit = 0 means „no”.
c  Partial hit; partial mapping of the hypothesis. Partial hit = 1 means „yes” and partial hit = 0 means „no”.
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Fig. 2. Overlay of the standard compounds, viz., a) phenobarbital, b) phenytoin, c) ralitolin and d) 
carbamazepine used in this study.
As shown in Table IV, compounds show high selectivity at GABA-AT with interactions of 
the important amino acids Arg-192, Ser-137, Thr-353 and Lys-329. Compounds 5c (Moldock 
score –334.844 and re-rank score –188.461) and compound 5i (Moldock score –314.576 and 
re-rank score –163.085) showed excellent binding interactions compared to the internal 
standard/ reference compound phenytoin (Moldock score –291.531and re-rank score 
–244.326). Molecular interactions of these compounds in close proximity of Lys-329 explain 
the high GABA-AT selectivity. The docking poses of compounds 5c, 5i and phenytoin are 
shown in Fig. 4. The internal aldimine linkage between Lys-329 and pyridoxal 5′-phos-
phate cofactor of the enzyme was broken. Instead, a covalent ternary adduct was formed 
between the inhibitor and the lysine residue. The affinity of these compounds with respect 
to the known standard drugs from this category was carried out in a Molegro virtual 
docker. It shows that these compounds have comparatively good binding affinities in the 
GABA-AT active site. The results of the docking studies are represented in Fig. 3 and Ta-
bles IV and V.
369
A.-K. Shakya et al.: Design, synthesis and evaluation of benzofuran-acetamide scaffold as potential anticonvulsant agent, Acta Pharm. 
66 (2016) 353–372.
 
Table V. Docking based predicted potencies in terms of the Moldock score, re-rank score and binding affinities 
of the synthesized compounds and of standard reference compounds
Compd. Moldock score Re-rank score Binding affinity predicted
5c –334.844 –188.461 –26.8359
5i –314.576 –163.085 –35.4334
Phenytoin –291.531 –244.326 –34.7004
Carbamazepine –201.409 –129.489 –31.6291
Phenobarbital –202.81 –169.056 –21.9851
Ralitolin –249.683 –188.369 –30.9745
Fig. 3. Docking predicted poses and interac-
tions between: a) compound 5c, b) compound 
5i and c) phenytoin, and amino acids in the 
active site of 4-aminobutyrate-aminotransfer-
ase (GABA-AT) (PDB code 1OHV).






In the present study, a series of benzofuran derivatives were synthesized, character-
ized and evaluated for their anticonvulsant activity. The title compounds (4a-l, 5a-l) fulfill 
all the pharmacophoric structural requirements, i.e., the presence of benzofuran as the 
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hydrophobic portion, C=O as the hydrogen bond acceptor, NHCO or the terminal nitrogen 
as the hydrogen bond donor and the hydrophobic aryl ring responsible for metabolism, 
which were well corroborated by the known standard drugs. The majority of the com-
pounds demonstrated significant anticonvulsant activity, although lower than that of the 
reference compound phenytoin. Strategic manipulation is required to synthesize com-
pounds with enhanced activity and lower neurotoxicity. Based on our docking results, the 
binding interactions and the occupation of these compounds in the active site by residues 
and the binding affinities with respect to standard compounds will provide a new direc-
tion for further standardization of these molecules.
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